<a href="https://www.fiercebiotech.com/biotech/contineums-jj-partnered-ms-drug-fails-improve-vision-phase-2" hreflang="en">Contineum's J&J-partnered MS drug fails to improve vision in phase 2</a>
Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis.